 | • レポートコード：MRC2312MG00427 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥721,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の組換えリツキシマブ注射剤市場規模と予測を収録しています。・世界の組換えリツキシマブ注射剤市場：売上、2018年-2023年、2024年-2029年 ・世界の組換えリツキシマブ注射剤市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の組換えリツキシマブ注射剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「100mg」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 組換えリツキシマブ注射剤のグローバル主要企業は、Roche、 Pfizer、 Amgen、 Celltrion Healthcare、 Henlius、 Innovent Biologicsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、組換えリツキシマブ注射剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の組換えリツキシマブ注射剤市場：タイプ別、2018年-2023年、2024年-2029年 世界の組換えリツキシマブ注射剤市場：タイプ別市場シェア、2022年 ・100mg、500mg 世界の組換えリツキシマブ注射剤市場：用途別、2018年-2023年、2024年-2029年 世界の組換えリツキシマブ注射剤市場：用途別市場シェア、2022年 ・病院、診療所、その他 世界の組換えリツキシマブ注射剤市場：地域・国別、2018年-2023年、2024年-2029年 世界の組換えリツキシマブ注射剤市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における組換えリツキシマブ注射剤のグローバル売上、2018年-2023年 ・主要企業における組換えリツキシマブ注射剤のグローバル売上シェア、2022年 ・主要企業における組換えリツキシマブ注射剤のグローバル販売量、2018年-2023年 ・主要企業における組換えリツキシマブ注射剤のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Roche、 Pfizer、 Amgen、 Celltrion Healthcare、 Henlius、 Innovent Biologics ************************************************************* ・調査・分析レポートの概要 組換えリツキシマブ注射剤市場の定義 市場セグメント 世界の組換えリツキシマブ注射剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の組換えリツキシマブ注射剤市場規模 世界の組換えリツキシマブ注射剤市場規模：2022年 VS 2029年 世界の組換えリツキシマブ注射剤市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの組換えリツキシマブ注射剤の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の組換えリツキシマブ注射剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：100mg、500mg 組換えリツキシマブ注射剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、診療所、その他 組換えリツキシマブ注射剤の用途別グローバル売上・予測 ・地域別市場分析 地域別組換えリツキシマブ注射剤市場規模 2022年と2029年 地域別組換えリツキシマブ注射剤売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Roche、 Pfizer、 Amgen、 Celltrion Healthcare、 Henlius、 Innovent Biologics ... |
This research report provides a comprehensive analysis of the Recombinant Rituximab Injection market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Recombinant Rituximab Injection market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Recombinant Rituximab Injection, challenges faced by the industry, and potential opportunities for market players.
The global Recombinant Rituximab Injection market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Recombinant Rituximab Injection market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Recombinant Rituximab Injection market. Additionally, the growing consumer demand present avenues for market expansion.
The global Recombinant Rituximab Injection market was valued at US$ 1277.1 million in 2022 and is projected to reach US$ 1716.1 million by 2029, at a CAGR of 4.3% during the forecast period.
Recombinant Rituximab Injection is a significant biopharmaceutical product widely used for the treatment of various autoimmune diseases and malignant tumors. The market for this product is substantial and continuously growing due to the increasing demand for healthcare. In the future, it is expected that this field will continue to evolve, with specific uses of Rituximab Injection potentially expanding to include the treatment of more autoimmune diseases, presenting additional business opportunities in the biopharmaceutical industry.
Key Features:
The research report on the Recombinant Rituximab Injection market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Recombinant Rituximab Injection market.
Market Overview: The report provides a comprehensive overview of the Recombinant Rituximab Injection market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., 100mg, 500mg), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Recombinant Rituximab Injection market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Recombinant Rituximab Injection market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Recombinant Rituximab Injection market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Recombinant Rituximab Injection market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Recombinant Rituximab Injection market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Recombinant Rituximab Injection market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Recombinant Rituximab Injection, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Recombinant Rituximab Injection market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Recombinant Rituximab Injection market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
100mg
500mg
Market segment by Application
Hospital
Clinic
Others
Global Recombinant Rituximab Injection Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Roche
Pfizer
Amgen
Celltrion Healthcare
Henlius
Innovent Biologics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Rituximab Injection, market overview.
Chapter 2: Global Recombinant Rituximab Injection market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Rituximab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Rituximab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Rituximab Injection capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Recombinant Rituximab Injection Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Recombinant Rituximab Injection Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Recombinant Rituximab Injection Overall Market Size
2.1 Global Recombinant Rituximab Injection Market Size: 2022 VS 2029
2.2 Global Recombinant Rituximab Injection Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Recombinant Rituximab Injection Sales: 2018-2029
3 Company Landscape
3.1 Top Recombinant Rituximab Injection Players in Global Market
3.2 Top Global Recombinant Rituximab Injection Companies Ranked by Revenue
3.3 Global Recombinant Rituximab Injection Revenue by Companies
3.4 Global Recombinant Rituximab Injection Sales by Companies
3.5 Global Recombinant Rituximab Injection Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Recombinant Rituximab Injection Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Recombinant Rituximab Injection Product Type
3.8 Tier 1, Tier 2 and Tier 3 Recombinant Rituximab Injection Players in Global Market
3.8.1 List of Global Tier 1 Recombinant Rituximab Injection Companies
3.8.2 List of Global Tier 2 and Tier 3 Recombinant Rituximab Injection Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Recombinant Rituximab Injection Market Size Markets, 2022 & 2029
4.1.2 100mg
4.1.3 500mg
4.2 By Type – Global Recombinant Rituximab Injection Revenue & Forecasts
4.2.1 By Type – Global Recombinant Rituximab Injection Revenue, 2018-2023
4.2.2 By Type – Global Recombinant Rituximab Injection Revenue, 2024-2029
4.2.3 By Type – Global Recombinant Rituximab Injection Revenue Market Share, 2018-2029
4.3 By Type – Global Recombinant Rituximab Injection Sales & Forecasts
4.3.1 By Type – Global Recombinant Rituximab Injection Sales, 2018-2023
4.3.2 By Type – Global Recombinant Rituximab Injection Sales, 2024-2029
4.3.3 By Type – Global Recombinant Rituximab Injection Sales Market Share, 2018-2029
4.4 By Type – Global Recombinant Rituximab Injection Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Recombinant Rituximab Injection Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application – Global Recombinant Rituximab Injection Revenue & Forecasts
5.2.1 By Application – Global Recombinant Rituximab Injection Revenue, 2018-2023
5.2.2 By Application – Global Recombinant Rituximab Injection Revenue, 2024-2029
5.2.3 By Application – Global Recombinant Rituximab Injection Revenue Market Share, 2018-2029
5.3 By Application – Global Recombinant Rituximab Injection Sales & Forecasts
5.3.1 By Application – Global Recombinant Rituximab Injection Sales, 2018-2023
5.3.2 By Application – Global Recombinant Rituximab Injection Sales, 2024-2029
5.3.3 By Application – Global Recombinant Rituximab Injection Sales Market Share, 2018-2029
5.4 By Application – Global Recombinant Rituximab Injection Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Recombinant Rituximab Injection Market Size, 2022 & 2029
6.2 By Region – Global Recombinant Rituximab Injection Revenue & Forecasts
6.2.1 By Region – Global Recombinant Rituximab Injection Revenue, 2018-2023
6.2.2 By Region – Global Recombinant Rituximab Injection Revenue, 2024-2029
6.2.3 By Region – Global Recombinant Rituximab Injection Revenue Market Share, 2018-2029
6.3 By Region – Global Recombinant Rituximab Injection Sales & Forecasts
6.3.1 By Region – Global Recombinant Rituximab Injection Sales, 2018-2023
6.3.2 By Region – Global Recombinant Rituximab Injection Sales, 2024-2029
6.3.3 By Region – Global Recombinant Rituximab Injection Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Recombinant Rituximab Injection Revenue, 2018-2029
6.4.2 By Country – North America Recombinant Rituximab Injection Sales, 2018-2029
6.4.3 US Recombinant Rituximab Injection Market Size, 2018-2029
6.4.4 Canada Recombinant Rituximab Injection Market Size, 2018-2029
6.4.5 Mexico Recombinant Rituximab Injection Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Recombinant Rituximab Injection Revenue, 2018-2029
6.5.2 By Country – Europe Recombinant Rituximab Injection Sales, 2018-2029
6.5.3 Germany Recombinant Rituximab Injection Market Size, 2018-2029
6.5.4 France Recombinant Rituximab Injection Market Size, 2018-2029
6.5.5 U.K. Recombinant Rituximab Injection Market Size, 2018-2029
6.5.6 Italy Recombinant Rituximab Injection Market Size, 2018-2029
6.5.7 Russia Recombinant Rituximab Injection Market Size, 2018-2029
6.5.8 Nordic Countries Recombinant Rituximab Injection Market Size, 2018-2029
6.5.9 Benelux Recombinant Rituximab Injection Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Recombinant Rituximab Injection Revenue, 2018-2029
6.6.2 By Region – Asia Recombinant Rituximab Injection Sales, 2018-2029
6.6.3 China Recombinant Rituximab Injection Market Size, 2018-2029
6.6.4 Japan Recombinant Rituximab Injection Market Size, 2018-2029
6.6.5 South Korea Recombinant Rituximab Injection Market Size, 2018-2029
6.6.6 Southeast Asia Recombinant Rituximab Injection Market Size, 2018-2029
6.6.7 India Recombinant Rituximab Injection Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Recombinant Rituximab Injection Revenue, 2018-2029
6.7.2 By Country – South America Recombinant Rituximab Injection Sales, 2018-2029
6.7.3 Brazil Recombinant Rituximab Injection Market Size, 2018-2029
6.7.4 Argentina Recombinant Rituximab Injection Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Recombinant Rituximab Injection Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Recombinant Rituximab Injection Sales, 2018-2029
6.8.3 Turkey Recombinant Rituximab Injection Market Size, 2018-2029
6.8.4 Israel Recombinant Rituximab Injection Market Size, 2018-2029
6.8.5 Saudi Arabia Recombinant Rituximab Injection Market Size, 2018-2029
6.8.6 UAE Recombinant Rituximab Injection Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Recombinant Rituximab Injection Major Product Offerings
7.1.4 Roche Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Recombinant Rituximab Injection Major Product Offerings
7.2.4 Pfizer Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Amgen
7.3.1 Amgen Company Summary
7.3.2 Amgen Business Overview
7.3.3 Amgen Recombinant Rituximab Injection Major Product Offerings
7.3.4 Amgen Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.3.5 Amgen Key News & Latest Developments
7.4 Celltrion Healthcare
7.4.1 Celltrion Healthcare Company Summary
7.4.2 Celltrion Healthcare Business Overview
7.4.3 Celltrion Healthcare Recombinant Rituximab Injection Major Product Offerings
7.4.4 Celltrion Healthcare Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.4.5 Celltrion Healthcare Key News & Latest Developments
7.5 Henlius
7.5.1 Henlius Company Summary
7.5.2 Henlius Business Overview
7.5.3 Henlius Recombinant Rituximab Injection Major Product Offerings
7.5.4 Henlius Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.5.5 Henlius Key News & Latest Developments
7.6 Innovent Biologics
7.6.1 Innovent Biologics Company Summary
7.6.2 Innovent Biologics Business Overview
7.6.3 Innovent Biologics Recombinant Rituximab Injection Major Product Offerings
7.6.4 Innovent Biologics Recombinant Rituximab Injection Sales and Revenue in Global (2018-2023)
7.6.5 Innovent Biologics Key News & Latest Developments
8 Global Recombinant Rituximab Injection Production Capacity, Analysis
8.1 Global Recombinant Rituximab Injection Production Capacity, 2018-2029
8.2 Recombinant Rituximab Injection Production Capacity of Key Manufacturers in Global Market
8.3 Global Recombinant Rituximab Injection Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Recombinant Rituximab Injection Supply Chain Analysis
10.1 Recombinant Rituximab Injection Industry Value Chain
10.2 Recombinant Rituximab Injection Upstream Market
10.3 Recombinant Rituximab Injection Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Recombinant Rituximab Injection Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer